Oncology On The Go

Fareed Khawaja, MBBS, assistant professor in the Department of Infectious Diseases, Infection Control, and Employee Health at The University of Texas MD Anderson Cancer Center, and Marilyne Daher, MD, medical resident in the Department of Internal Medicine at Baylor College of Medicine, spoke with CancerNetwork® about their study titled COVID-19 Vaccination in Patients with Cancer and Recipients of Cellular Therapy, which was published in the journal ONCOLOGY®.


In their study, Khawaja and Daher gave an overview of the current COVID-19 vaccines that are available in the United States, published data on vaccine efficacy and safety in patients with cancer, current vaccination guidelines, and future strategies for preventing COVID-19–related complications. 


Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

In a conversation with CancerNetwork® during March’s Myeloma Awareness Month, Krina Patel, MD, MSc, spoke about disparities in outcomes and clinical trial access for patients with multiple myeloma.


Patel, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed previous research focusing on how factors including gender, race, and ethnicity correlated with treatment outcomes with autologous hemopoietic stem cell transplantation and CAR T-cell therapy. 


She also detailed ongoing efforts from organizations such as the FDA and the International Myeloma Foundation on increasing enrollment of underserved patient groups on clinical trials as well as financial initiatives that may help to reduce barriers to treatment including transportation. 


Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

As part of Kidney Cancer Awareness Month 2023, Santosh Rao, MD, spoke with CancerNetwork® about recent developments and initiatives that have helped to advance integrative and palliative care for patients with kidney cancer, including developments that read out of the Annual Society for Integrative Oncology (SIO) International Conference and evidence supporting the use of non-clinical tools such as acupuncture, reflexology, acupressure, and massages. 


Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the SIO, outlined palliative care strategies employed at University Hospitals and described ongoing research and pain management guidelines that aim to improve integrative care in kidney cancer. 


Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Minh-Tri Nguyen, MD, a hematology and oncology fellow at Cleveland Clinic Taussig Cancer Institute, spoke with CancerNetwork® about his study titled Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors, which was published in the journal ONCOLOGY®.


In his study, Nguyen and his colleagues explored factors including time to treatment initiation as predictors of overall survival in rural and nonrural patients with breast cancer. Overall, their research suggested that improving time to treatment initiation can mitigate socioeconomic disparities observed in rural cancer care. 


Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

In a Twitter Spaces edition of the Oncology On-the-Go podcast, Kevin Kalinsky, MD, MS, and Jane Meisel, MD, of Emory Winship Cancer Institute, spoke with CancerNetwork® about how the FDA approval of sacituzumab govitecan-hziy (Trodlevy) for advanced or metastatic hormone receptor–positive, HER2-negative breast cancer will impact the treatment paradigm.


Kalinsky, an associate professor in the Department of Hematology and Medical Oncology and director of Breast Medical Oncology, and Meisel, an associate professor in the Department of Hematology and Medical Oncology and in the Department of Gynecology and Obstetrics, discussed data from the phase 3 TROPiCS-02 trial (NCT03901339) that led to the approval and what unmet needs still exist in the space.


Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Julianne Cooley, MS, a computational and data science research specialist at the California Cancer Reporting and Epidemiologic Surveillance in the University of California Davis Comprehensive Cancer Center, spoke with CancerNetwork® about her research on cervical cancer screening and survival rate patterns among patients 65 years and older. 


In her study, Cooley explored how survival rates among older patients with late-stage cervical cancer diagnoses were lower compared with those of younger patients, and how the current screening paradigm may be impacting this older population. 


Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Yancey Warren, Jr, MD, MAT, a breast surgery oncology fellow at Brown University, and Lejla Hadzikadic-Gusic, MD, MSc, associate professor of surgery, Division of Surgical Oncology at Atrium Health Levine Cancer Institute, spoke with CancerNetwork® about their study titled Integrative Oncology in Young Women with Breast Cancer, which was published in the journal ONCOLOGY®.
In their study, the authors explored the potential benefit of integrative oncology strategies to better establish referral practices for Levine Cancer Institute and define optimal timing for treatment in young patients with breast cancer. 
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts,Spotify, or anywhere podcasts are available.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with several multidisciplinary oncology experts from the Mayo Clinic in Rochester, Minnesota about their respective key takeaways from the presentations on developments in the breast cancer space, including surgery, radiotherapy, and biomarker research. 
Judy C. Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery, discussed her research on the impact of breast conservation therapy on local recurrence rates in multiple ipsilateral breast cancer in the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243).
Robert Mutter, MD, an associate professor of the Department of Radiation Oncology, spoke about his work on a randomized phase 2 trial assessing the use of conventional vs hypofractionated proton radiotherapy following a mastectomy among patients with breast cancer. 
Siddhartha Yadav, MD, MBBS, a medical oncologist and assistant professor of Medicine and Oncology, highlighted data from the population-based CARRIERS study, assessing germline pathogenic variants and other factors as risks for contralateral breast cancer.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts,Spotify, or anywhere podcasts are available.

Ibrahim Halil Sahin, MD, a medical oncologist specializing in gastrointestinal oncology and an assistant professor at the University of Pittsburgh Medical Center, Hillman Cancer Center, spoke with CancerNetwork® about his manuscript titled Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US, which was recently published in the journal ONCOLOGY®.
In the article, Sahin and his colleagues explored postoperative circulating tumor DNA dynamics in early-stage colon cancer and investigated escalation and de-escalation approaches using ctDNA status as a surrogate for minimal residual disease status.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available. 

As part of the Between the Lines™ video series, Bruce Cheson, MD, FACP, FAAAS, FASCO, a board certified hematologist at the Center for Cancer and Blood Disorders in Bethesda, Maryland, spoke with Steven Park, MD, an oncologist and vice chair of Research at the Atrium Health Levine Cancer Institute and a clinical professor of Medicine at Wake Forest University. These experts shared their insight on the phase 1/2 E7438-G000-101 (NCT01897571) clinical trial and highlighted key data on tazemetostat (Tazverik), an EZH2 inhibitor, in relapsed or refractory follicular lymphoma.
In the video series, Cheson and Park discussed the following:
·      Overview of relapsed/refractory follicular lymphoma and available treatment options
·      Tazemetostat trial data and propensity score-matched analysis
·      Role of tazemetostat treatment moving forward

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.